Evidence map›Paper›PMID 41269436›Full record

ArticleMedical oncology (Northwood, London, England)2025

BNC2 as a novel driver of pancreatic cancer progression through transcriptional regulation of COL3A1 and epithelial-to-mesenchymal transition.

Xiuming Li, Teng Yu, Zien Yu, Xun Zou, Jingliang He, Dan Wang, Xiaozhu Shen, Shunfang Liu, Bin Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiuming Li *Jiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, College of Pharmacy, Jiangsu Ocean University, Lianyungang, 222005, China.
Teng Yu *Department of Pathology, Shanghai Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China.
Zien Yu *Jiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, College of Pharmacy, Jiangsu Ocean University, Lianyungang, 222005, China.
Xun ZouJiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, College of Pharmacy, Jiangsu Ocean University, Lianyungang, 222005, China.
Jingliang HeJiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, College of Pharmacy, Jiangsu Ocean University, Lianyungang, 222005, China.
Dan WangJiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, College of Pharmacy, Jiangsu Ocean University, Lianyungang, 222005, China.
Xiaozhu ShenDepartment of Geriatrics, Lianyungang Second People's Hospital, Lianyungang, 222005, China. shenxiaozhu@lygey.com.
Shunfang LiuDepartment of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. liushunfang28@163.com.
Bin LiuJiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, College of Pharmacy, Jiangsu Ocean University, Lianyungang, 222005, China. liubin@jou.edu.cn.

Funding

Chen Xiao-Ping Foundation for the Development of Science and Technology of Hubei Province CXPJJH123003-027"Huaguo Mountain Talent Plan" of Lianyungang City NoneHubei Provincial Natural Science Foundation of China 2025AFB476Key Program of Basic Science (Natural Science) of Jiangsu Province 22KJA350001Lianyungang Ageing Health Research Project L202304Lianyungang Traditional Chinese Medicine Science and Technology Development Program Project ZD202310Postgraduate Research & Practice Innovation Program of Jiangsu Ocean University KYCX2024-70Scientific Research Fund of Tongji Hospital 2023A09
6 · The paper itself

Abstract

Pancreatic cancer remains one of the deadliest malignancies due to its high metastatic potential and resistance to treatment. Transcription factors driving epithelial-to-mesenchymal transition (EMT) are critical in promoting invasion and metastasis, yet their full repertoire remains poorly understood. Here, we identify Basonuclin 2 (BNC2), a zinc-finger transcription factor, as a novel regulator of pancreatic cancer progression. Through integrative transcriptomic analyses, we demonstrate that BNC2 is significantly upregulated in pancreatic cancer and correlates with advanced tumor grade, stage, and poor prognosis. Functional assays reveal that BNC2 promotes EMT and cancer cell invasion by transcriptionally activating collagen type III alpha 1 (COL3A1), a key extracellular matrix component. Knockdown of BNC2 suppresses EMT, reduces invasiveness, and downregulates COL3A1, whereas COL3A1 overexpression rescues these effects, establishing the BNC2-COL3A1 axis as a critical driver of tumor progression. These findings highlight BNC2 as a potential biomarker and therapeutic target in pancreatic cancer, offering new insights into the molecular mechanisms underlying this aggressive disease.

Indexed as

Collagen Type IIIDNA-Binding ProteinsEpithelial-Mesenchymal TransitionPancreatic NeoplasmsTranscription FactorsBiomarkers, TumorCell Line, TumorDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansMaleNeoplasm InvasivenessPrognosisBiomarkers, TumorCOL3A1 protein, humanCollagen Type IIIDNA-Binding ProteinsTranscription FactorsBNC2COL3A1EMTPancreatic cancerTranscription factorTumor progression

Identifiers

PMID41269436

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.